Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

James Young Biography and Net Worth

Director of Novavax

Dr. Young joined the Novavax board of directors in April 2010 and was appointed chairman in April 2011. He has more than 30 years of experience in the fields of molecular genetics, microbiology, immunology, and pharmaceutical development. Most recently, Dr. Young was MedImmune’s president of research and development, where he had responsibility for regulatory affairs and was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics. Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York City, New York. He received his bachelor of science degrees in biology and general sciences from Villanova University and a doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas.

What is James F. Young's net worth?: The estimated net worth of James F. Young is at least $537,312.00 as of June 21st, 2024. Dr. Young owns 61,760 shares of Novavax stock worth more than $537,312 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Young may own. Learn More about James F. Young's net worth.
How do I contact James F. Young?: The corporate mailing address for Dr. Young and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on James F. Young's contact information.
Has James F. Young been buying or selling shares of Novavax?: James F. Young has not been actively trading shares of Novavax during the last quarter. Most recently, James F. Young sold 7,500 shares of the business's stock in a transaction on Friday, June 21st. The shares were sold at an average price of $14.09, for a transaction totalling $105,675.00. Following the completion of the sale, the director now directly owns 61,760 shares of the company's stock, valued at $870,198.40. Learn More on James F. Young's trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 62,312 shares worth more than $866,211.80. The most recent insider tranaction occured on June, 21st when Director James F Young sold 7,500 shares worth more than $105,675.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 6/21/2024.

James F. Young Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2024	Sell	7,500	$14.09	$105,675.00	61,760
6/18/2024	Sell	7,500	$13.72	$102,900.00	69,260
3/31/2022	Sell	12,500	$73.58	$919,750.00	62,590
3/23/2021	Sell	10,000	$228.22	$2,282,200.00	20,000
6/3/2020	Buy	1,500	$48.83	$73,245.00
8/31/2017	Sell	175,000	$1.06	$185,500.00
6/18/2015	Sell	50,000	$9.47	$473,500.00
6/6/2013	Buy	100,000	$1.91	$191,000.00
3/11/2013	Buy	100,000	$2.03	$203,000.00

James F. Young Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $8.70

$8.37

$8.89

50 Day Range

MA: $9.13

$7.22

$12.62

2 Week Range

Now: $8.70

$3.53

$23.86

Volume

6,086,848 shs

Average Volume

9,218,745 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02